Cargando…
Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation
Human hepatocellular carcinomas (HCCs), which arise on a background of chronic liver damage and inflammation, express c-Fos, a component of the AP-1 transcription factor. Using mouse models, we show that hepatocyte-specific deletion of c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, wh...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413325/ https://www.ncbi.nlm.nih.gov/pubmed/28356389 http://dx.doi.org/10.1084/jem.20160935 |
_version_ | 1783233168333078528 |
---|---|
author | Bakiri, Latifa Hamacher, Rainer Graña, Osvaldo Guío-Carrión, Ana Campos-Olivas, Ramón Martinez, Lola Dienes, Hans P. Thomsen, Martin K. Hasenfuss, Sebastian C. Wagner, Erwin F. |
author_facet | Bakiri, Latifa Hamacher, Rainer Graña, Osvaldo Guío-Carrión, Ana Campos-Olivas, Ramón Martinez, Lola Dienes, Hans P. Thomsen, Martin K. Hasenfuss, Sebastian C. Wagner, Erwin F. |
author_sort | Bakiri, Latifa |
collection | PubMed |
description | Human hepatocellular carcinomas (HCCs), which arise on a background of chronic liver damage and inflammation, express c-Fos, a component of the AP-1 transcription factor. Using mouse models, we show that hepatocyte-specific deletion of c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, whereas liver-specific c-Fos expression leads to reversible premalignant hepatocyte transformation and enhanced DEN-carcinogenesis. c-Fos–expressing livers display necrotic foci, immune cell infiltration, and altered hepatocyte morphology. Furthermore, increased proliferation, dedifferentiation, activation of the DNA damage response, and gene signatures of aggressive HCCs are observed. Mechanistically, c-Fos decreases expression and activity of the nuclear receptor LXRα, leading to increased hepatic cholesterol and accumulation of toxic oxysterols and bile acids. The phenotypic consequences of c-Fos expression are partially ameliorated by the anti-inflammatory drug sulindac and largely prevented by statin treatment. An inverse correlation between c-FOS and the LXRα pathway was also observed in human HCC cell lines and datasets. These findings provide a novel link between chronic inflammation and metabolic pathways important in liver cancer. |
format | Online Article Text |
id | pubmed-5413325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54133252017-11-01 Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation Bakiri, Latifa Hamacher, Rainer Graña, Osvaldo Guío-Carrión, Ana Campos-Olivas, Ramón Martinez, Lola Dienes, Hans P. Thomsen, Martin K. Hasenfuss, Sebastian C. Wagner, Erwin F. J Exp Med Research Articles Human hepatocellular carcinomas (HCCs), which arise on a background of chronic liver damage and inflammation, express c-Fos, a component of the AP-1 transcription factor. Using mouse models, we show that hepatocyte-specific deletion of c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, whereas liver-specific c-Fos expression leads to reversible premalignant hepatocyte transformation and enhanced DEN-carcinogenesis. c-Fos–expressing livers display necrotic foci, immune cell infiltration, and altered hepatocyte morphology. Furthermore, increased proliferation, dedifferentiation, activation of the DNA damage response, and gene signatures of aggressive HCCs are observed. Mechanistically, c-Fos decreases expression and activity of the nuclear receptor LXRα, leading to increased hepatic cholesterol and accumulation of toxic oxysterols and bile acids. The phenotypic consequences of c-Fos expression are partially ameliorated by the anti-inflammatory drug sulindac and largely prevented by statin treatment. An inverse correlation between c-FOS and the LXRα pathway was also observed in human HCC cell lines and datasets. These findings provide a novel link between chronic inflammation and metabolic pathways important in liver cancer. The Rockefeller University Press 2017-05-01 /pmc/articles/PMC5413325/ /pubmed/28356389 http://dx.doi.org/10.1084/jem.20160935 Text en © 2017 Bakiri et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Bakiri, Latifa Hamacher, Rainer Graña, Osvaldo Guío-Carrión, Ana Campos-Olivas, Ramón Martinez, Lola Dienes, Hans P. Thomsen, Martin K. Hasenfuss, Sebastian C. Wagner, Erwin F. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title_full | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title_fullStr | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title_full_unstemmed | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title_short | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
title_sort | liver carcinogenesis by fos-dependent inflammation and cholesterol dysregulation |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413325/ https://www.ncbi.nlm.nih.gov/pubmed/28356389 http://dx.doi.org/10.1084/jem.20160935 |
work_keys_str_mv | AT bakirilatifa livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT hamacherrainer livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT granaosvaldo livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT guiocarrionana livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT camposolivasramon livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT martinezlola livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT dieneshansp livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT thomsenmartink livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT hasenfusssebastianc livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation AT wagnererwinf livercarcinogenesisbyfosdependentinflammationandcholesteroldysregulation |